ADELA | Home

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [elderly couple smiling]

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests

Adela's platform can be applied across the cancer continuum

With a single, scalable platform, Adela is poised to address the unmet need broadly across multiple cancers and applications

Detect minimal residual disease (MRD) following surgery to guide use of adjuvant treatment and monitor for recurrence

Monitor for response in patients receiving immunotherapy

Early identification of multiple types of cancer for screening and detection

Adela’s mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being.

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [father and child playing guitar]

RECENT UPDATES

March 3, 2026

Adela Announces Study Published in NPJ Precision Oncology Clinically Validating its Tissue-Free Test to Monitor Immunotherapy Response in Advanced Solid Tumors

May 30, 2025

Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting

April 28, 2025

Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025